Cargando…

Impact of Low-Burden TP53 Mutations in the Management of CLL

In chronic lymphocytic leukemia (CLL), TP53 abnormalities are associated with reduced survival and resistance to chemoimmunotherapy (CIT). The recommended threshold to clinically report TP53 mutations is a matter of debate given that next-generation sequencing technologies can detect mutations with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazarian, Gregory, Cymbalista, Florence, Baran-Marszak, Fanny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861357/ https://www.ncbi.nlm.nih.gov/pubmed/35211418 http://dx.doi.org/10.3389/fonc.2022.841630

Ejemplares similares

PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
por: Taleb, Assia, et al.
Publicado: (2023)

Genetic profiling of CLL: a ‘TP53 addict' perspective
por: Lodé, L, et al.
Publicado: (2016)

TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
por: Catherwood, Mark A., et al.
Publicado: (2022)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
por: Li, Yanong, et al.
Publicado: (2021)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
por: Nguyen-Khac, Florence
Publicado: (2022)

Current insights into the regulation of programmed cell death by TP53 mutation in cancer
por: Su, Yali, et al.
Publicado: (2022)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

Corrigendum: Current insights into the regulation of programmed cell death by TP53 mutation in cancer
por: Su, Yali, et al.
Publicado: (2022)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

TP53 Status is Associated with Thrombospondin1 Expression In vitro
por: Alvarez Secord, Angeles, et al.
Publicado: (2013)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases
por: Soussi, Thierry, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
por: Gao, Jing, et al.
Publicado: (2021)

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma
por: Boukhiar, Mohand-Akli, et al.
Publicado: (2013)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma
por: Dong, Mingwei, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

P961: BORTEZOMIB, RITUXIMAB AND DEXAMETHASONE REGIMEN (BDR) IN WALDENSTRÖM MACROGLOBULINEMIA: A RETROSPECTIVE ANALYSIS
por: Hueso, Thomas, et al.
Publicado: (2023)

Case Report: A novel TP53 mutation in a patient with quadruple wild-type gastrointestinal stromal tumor
por: Chen, Yuhong, et al.
Publicado: (2023)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Alsaihati, Burair A., et al.
Publicado: (2021)

STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation
por: Hu, Shanshan, et al.
Publicado: (2020)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
por: Grill, Sabine, et al.
Publicado: (2020)

Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53
por: Butz, Henriett, et al.
Publicado: (2022)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i4o4vnr6q41bjo81ljrfo5m412